Aveanna Healthcare (AVAH) 10-Q 15 Nov 22 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 01, 2022	Nov. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 01, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Aveanna Healthcare Holdings Inc.
Entity Central Index Key	0001832332
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		185,918,240
Entity File Number	001-40362
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-4717209
Entity Address, Address Line One	400 Interstate North Parkway SE
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	770
Local Phone Number	441-1580
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	AVAH
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 01, 2022	Jan. 01, 2022
Current assets:
Cash and cash equivalents	$ 63,681	$ 30,490
Patient accounts receivable	219,246	218,917
Receivables under insured programs	6,789	6,373
Prepaid expenses	12,604	14,233
Other current assets	9,764	9,202
Total current assets	312,084	279,215
Property and equipment, net	24,919	31,374
Operating lease right of use assets	53,789	51,992
Goodwill	1,368,333	1,835,580
Intangible assets, net	97,779	102,851
Receivables under insured programs	23,970	25,530
Other long-term assets	92,495	7,829
Total assets	1,973,369	2,334,371
Current liabilities:
Accounts payable and other accrued liabilities	48,960	52,624
Accrued payroll and employee benefits	49,996	54,565
Current portion of insurance reserves - insured programs	6,789	6,373
Current portion of insurance reserves	17,326	13,466
Securitization obligations	140,000	120,000
Current portion of long-term obligations	9,200	8,600
Current portion of operating lease liabilities	12,496	13,534
Current portion of deferred payroll taxes	25,523	25,523
Other current liabilities	41,391	50,146
Total current liabilities	351,681	344,831
Long-term obligations, less current portion	1,282,603	1,226,517
Long-term insurance reserves - insured programs	23,970	25,530
Long-term insurance reserves	37,146	35,122
Operating lease liabilities, less current portion	44,518	44,682
Deferred income taxes	2,753	3,046
Other long-term liabilities	616	16,692
Total liabilities	1,743,287	1,696,420
Commitments and contingencies (Note 10)
Deferred restricted stock units	2,135	2,135
Stockholders’ equity:
Preferred stock, $0.01 par value as of October 1, 2022 and no par value as of January 1, 2022, 5,000,000 shares authorized; none issued or outstanding
Common stock, $0.01 par value, 1,000,000,000 shares authorized; 185,918,240 and 184,732,268 issued and outstanding, respectively	1,859	1,847
Additional paid-in capital	1,225,019	1,208,645
Accumulated deficit	(998,931)	(574,676)
Total stockholders’ equity	227,947	635,816
Total liabilities, deferred restricted stock units, and stockholders’ equity	$ 1,973,369	$ 2,334,371

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 01, 2022	Jan. 01, 2022
Statement of Financial Position [Abstract]
Preferred stock, no par value		$ 0
Preferred stock, par value	$ 0.01
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock,outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized	1,000,000,000	1,000,000,000
Common stock, Issued	185,918,240	184,732,268
Common stock, outstanding	185,918,240	184,732,268

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Income Statement [Abstract]
Revenue	$ 443,009	$ 411,276	$ 1,336,498	$ 1,264,548
Cost of revenue, excluding depreciation and amortization	308,426	271,534	912,046	846,534
Branch and regional administrative expenses	89,542	76,370	267,283	223,462
Corporate expenses	33,215	37,873	105,984	97,673
Goodwill impairment			470,207
Depreciation and amortization	4,917	5,145	16,774	15,163
Acquisition-related costs		2,007	69	4,779
Other operating expense	2,122		1,953
Operating income (loss)	4,787	18,347	(437,818)	76,937
Interest income	164	44	369	182
Interest expense	(28,462)	(12,106)	(73,745)	(53,793)
Loss on debt extinguishment		(4,784)		(13,702)
Other income (expense)	45,140	(511)	86,523	(1,088)
Income (Loss) before income taxes	21,629	990	(424,671)	8,536
Income tax benefit	2,669	1,100	416	612
Net income (loss)	$ 24,298	$ 2,090	$ (424,255)	$ 9,148
Net income (loss) per share:
Net income (loss) per share, basic	$ 0.13	$ 0.01	$ (2.29)	$ 0.06
Weighted average shares of common stock outstanding, basic	186,113	184,554	185,327	165,877
Net income (loss) per share, diluted	$ 0.13	$ 0.01	$ (2.29)	$ 0.05
Weighted average shares of common stock outstanding, diluted	186,166	188,246	185,327	170,667

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Jan. 02, 2021	$ 265,034	$ 1,419	$ 721,247	$ (457,632)
Beginning Balance (shares) at Jan. 02, 2021		141,928,184
Issuance of common stock, net of underwriters' discounts and commissions	470,108	$ 422	469,686
Issuance of common stock, net of underwriters' discounts and commissions (shares)		42,236,000
Non-cash share-based compensation	10,142		10,142
Net income (loss)	9,148			9,148
Ending Balance at Oct. 02, 2021	754,432	$ 1,841	1,201,075	(448,484)
Ending Balance (in shares) at Oct. 02, 2021		184,164,184
Beginning Balance at Jul. 03, 2021	748,080	$ 1,841	1,196,813	(450,574)
Beginning Balance (shares) at Jul. 03, 2021		184,164,184
Non-cash share-based compensation	4,262		4,262
Net income (loss)	2,090			2,090
Ending Balance at Oct. 02, 2021	754,432	$ 1,841	1,201,075	(448,484)
Ending Balance (in shares) at Oct. 02, 2021		184,164,184
Beginning Balance at Jan. 01, 2022	635,816	$ 1,847	1,208,645	(574,676)
Beginning Balance (shares) at Jan. 01, 2022		184,732,268
Employee stock purchase plan	2,278	$ 12	2,266
Employee stock purchase plan (shares)		1,185,972
Non-cash share-based compensation	14,108		14,108
Net income (loss)	(424,255)			(424,255)
Ending Balance at Oct. 01, 2022	227,947	$ 1,859	1,225,019	(998,931)
Ending Balance (in shares) at Oct. 01, 2022		185,918,240
Beginning Balance at Jul. 02, 2022	200,137	$ 1,859	1,221,507	(1,023,229)
Beginning Balance (shares) at Jul. 02, 2022		185,918,240
Non-cash share-based compensation	3,512		3,512
Net income (loss)	24,298			24,298
Ending Balance at Oct. 01, 2022	$ 227,947	$ 1,859	$ 1,225,019	$ (998,931)
Ending Balance (in shares) at Oct. 01, 2022		185,918,240

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Cash Flows From Operating Activities:
Net (loss) income	$ (424,255)	$ 9,148
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	16,774	15,163
Amortization of deferred debt issuance costs	5,221	7,234
Amortization and impairment of operating lease right of use assets	12,722	11,081
Non-cash share-based compensation	14,108	10,142
Goodwill impairment	470,207
Loss on disposal of licenses, property and equipment	1,985	109
Fair value adjustments on interest rate derivatives	(89,634)	(6,246)
Gain on sale of businesses	(170)
Loss on debt extinguishment		13,702
Deferred income taxes	(293)	839
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(921)	(3,376)
Prepaid expenses	6,825	2,715
Other current and long-term assets	(1,878)	39
Accounts payable and other accrued liabilities	(2,395)	(15,851)
Accrued payroll and employee benefits	(4,569)	(3,164)
Insurance reserves	5,884	2,752
Operating lease liabilities	(15,845)	(11,783)
Other current and long-term liabilities	(1,932)	(10,316)
Net cash (used in) provided by operating activities	(8,166)	22,188
Cash Flows From Investing Activities:
Acquisitions of businesses, net of cash acquired	(2,027)	(103,202)
Proceeds from sale of businesses	460
Payment for interest rate cap	(11,725)
Purchases of property and equipment	(8,800)	(10,306)
Net cash used in investing activities	(22,092)	(113,508)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock		477,688
Proceeds from employee stock purchase plan	2,278
Proceeds from securitization obligation	40,000
Repayment of securitization obligation	(20,000)
Proceeds from revolving credit facility	15,000
Repayments on revolving credit facility	(15,000)
Proceeds from issuance of term loans, net of debt issuance costs	59,700	925,261
Principal payments on term loans	(6,600)	(1,271,733)
Principal payments on notes payable	(7,564)	(4,910)
Repayment of government stimulus funds		(29,444)
Principal payments of financing lease obligations	(581)	(503)
Payment of offering costs		(5,473)
Payment of debt issuance costs	(218)	(13,107)
Settlements with derivative counterparties	(3,566)	(2,096)
Net cash provided by financing activities	63,449	75,683
Net increase (decrease) in cash and cash equivalents	33,191	(15,637)
Cash and cash equivalents at beginning of period	30,490	137,345
Cash and cash equivalents at end of period	63,681	121,708
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	69,572	47,156
Acquisition of property and equipment on accrual	502	3,246
Offering costs included in accounts payable and other accrued liabilities		135
Cash paid for income taxes, net of refunds received	$ 1,410	$ 3,915

Description of Business

Description of Business	9 Months Ended
	Oct. 01, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. DESCRIPTION OF BUSINESS Aveanna Healthcare Holdings Inc. (together with its consolidated subsidiaries, referred to herein as the “Company”) is headquartered in Atlanta, Georgia and has locations in 33 states with concentrations in California, Texas and Pennsylvania, providing a broad range of pediatric and adult healthcare services including nursing, hospice, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying interim unaudited consolidated financial statements include the accounts of Aveanna Healthcare Holdings Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in the accompanying interim unaudited consolidated financial statements, and business combinations accounted for as purchases have been included in the accompanying interim unaudited consolidated financial statements from their respective dates of acquisition. Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these interim unaudited consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, these interim unaudited consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the Company’s financial position as of October 1, 2022 and the results of operations for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively. The results reported in these interim unaudited consolidated financial statements should not be regarded as indicative of results that may be expected for any other period or the entire year. These interim unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes for the fiscal year ended January 1, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 28, 2022. Our fiscal year ends on the Saturday that is closest to December 31 of a given year, resulting in either a 52 or 53-week fiscal year. The accompanying interim unaudited consolidated balance sheets reflect the accounts of the Company as of October 1, 2022 and January 1, 2022. For the three-month periods ended October 1, 2022 and October 2, 2021, the accompanying interim unaudited consolidated statements of operations, stockholders’ equity and cash flows reflect the accounts of the Company from July 2, 2022 through October 1, 2022 and July 3, 2021 through October 2, 2021, respectively. For the nine-month periods ended October 1, 2022 and October 2, 2021, the accompanying interim unaudited consolidated statements of operations, stockholders' equity and cash flows reflect the accounts of the Company from January 2, 2022 through October 1, 2022 and January 3, 2021 through October 2, 2021 , respectively. Use of Estimates The Company’s accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, the Company is required to make estimates and assumptions that impact the amounts reported in these consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. An entity may adopt this ASU as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the impact of adopting this standard. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope , to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. This ASU is effective immediately and should be adopted in conjunction with ASU 2020-04. The Company is currently evaluating the impact of adopting this standard.

Revenue

Revenue	9 Months Ended
	Oct. 01, 2022
Revenue from Contract with Customer [Abstract]
Revenue	3. REVENUE The Company evaluated the nature, amount, timing and uncertainty of revenue and cash flows using the five-step process. The Company uses a portfolio approach to group contracts with similar characteristics and analyze historical cash collection trends. Revenue is primarily derived from (i) pediatric healthcare services provided to patients including private duty nursing services, unskilled care, and therapy services; (ii) adult home health and hospice services (collectively “patient revenue”); and (iii) from the delivery of enteral nutrition and other products to patients (“product revenue”). The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each service provided is its own stand-alone contract. Incremental costs of obtaining a contract are expensed as incurred due to the short-term nature of the contracts. Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. For patient revenue, the performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For product revenue, the performance obligation is satisfied at the point in time of delivery of the product to the patient. The Company recognizes patient revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payers are billed within several days of the service being performed, and payments are due based on contract terms. The Company’s lines of business are generally classified into the following categories: private duty services; home health and hospice; and medical solutions. Private Duty Services (“PDS”). The PDS business includes a broad range of pediatric and adult healthcare services including private duty skilled nursing, unskilled services which include employer of record support services and personal care services, pediatric therapy services, rehabilitation services, and nursing services in schools and pediatric day healthcare centers. Home Health & Hospice (“HHH”) . The HHH business provides home health, hospice, and personal care services to predominately elderly patients. Medical Solutions (“MS”). The MS business includes the delivery of enteral nutrition and other products to patients. For the PDS, HHH, and MS businesses, the Company receives payments from the following sources for services rendered: (i) state governments under their respective Medicaid programs (“Medicaid”); (ii) managed care providers of state government Medicaid programs (“Medicaid MCO”); (iii) commercial insurers; (iv) other government programs including Medicare and Tricare and ChampVA (“Medicare”); and (v) individual patients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component. The Company determines the transaction price based on established billing rates reduced by explicit price concessions (contractual adjustments and discounts) provided to third-party payers and implicit price concessions. Explicit price concessions are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. As of October 1, 2022 and January 1, 2022, estimated explicit and implicit price concessions of $ 62.2 million and $ 55.8 million, respectively, were recorded as reductions to patient accounts receivable balances to arrive at the estimated collectible revenue and patient accounts receivable. Most contracts contain variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense which is included as a component of operating expenses in the consolidated statements of operations. The Company did no t record any bad debt expense for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively. The Company derives a significant portion of its revenue from Medicaid, Medicaid MCO, Medicare and other payers that receive discounts from established billing rates. The regulations and various managed care contracts under which these discounts must be estimated are complex and subject to interpretation. Management estimates the transaction price on a payer-specific basis given its interpretation of the applicable regulations or contract terms. Updated regulations and contract negotiations occur frequently, necessitating regular review and assessment of the estimation process by management; however, there were no material revenue adjustments recognized from performance obligations satisfied or partially satisfied in previous periods for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively. The following table presents revenue by payer type as a percentage of revenue for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively: For the three-month periods ended For the nine-month periods ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Percentage Percentage Percentage Percentage Medicaid MCO 50.9 % 53.3 % 51.6 % 53.9 % Medicaid 21.6 % 24.6 % 21.8 % 24.4 % Commercial 8.4 % 9.7 % 9.4 % 11.1 % Medicare 19.0 % 12.1 % 17.1 % 10.3 % Self-pay 0.1 % 0.3 % 0.1 % 0.3 % Total revenue 100.0 % 100.0 % 100.0 % 100.0 %

Long-Term Obligations

Long-Term Obligations	9 Months Ended
	Oct. 01, 2022
Debt Disclosure [Abstract]
Long-Term Obligations	4. LONG-TERM OBLIGATIONS Long-term obligations consisted of the following as of October 1, 2022 and January 1, 2022, respectively (dollar amounts in thousands): Instrument Stated Contractual Interest Rate Interest Rate October 1, 2022 January 1, 2022 2021 Extended Term Loan (1) 07/2028 L + 3.75 % 6.89 % $ 851,400 $ 857,850 Delayed Draw Term Loan (1) 07/2028 L + 3.75 % 6.89 % 59,850 - Second Lien Term Loan (1) 12/2029 L + 7.00 % 10.14 % 415,000 415,000 Revolving Credit Facility (1) 04/2026 L + 3.75 % 6.89 % - - Total principal amount of long-term obligations 1,326,250 1,272,850 Less: unamortized debt issuance costs ( 34,447 ) ( 37,733 ) Total amount of long-term obligations, net of unamortized debt issuance costs 1,291,803 1,235,117 Less: current portion of long-term obligations ( 9,200 ) ( 8,600 ) Total amount of long-term obligations, net of unamortized debt issuance costs, less current portion $ 1,282,603 $ 1,226,517 (1) L = Greater of 0.50% or one-month LIBOR The 2021 Extended Term Loan, Revolving Credit Facility and any Delayed Draw Term Loans bear interest, at the Company’s election, at a variable interest rate based on either LIBOR (subject to a minimum of 0.50 % ), or Annual Base Rate ("ABR") (subject to a minimum of 2.00 % ) for the interest period relevant to such borrowing, plus an applicable margin of 3.75 % for loans accruing interest based on LIBOR and an applicable margin of 2.75 % for loans accruing interest based on ABR. On August 9, 2022, the Company borrowed $ 60.0 million under the Delayed Draw Term Loan, the terms of which are similar to those of the 2021 Extended Term Loan. The remaining available borrowing base of $ 140.0 million under the Delayed Draw Term Loan is available until July 15, 2023, subject to certain terms and conditions. The Second Lien Term Loan bears interest at a rate per annum equal to, at the Company’s option, either (1) an applicable margin (equal to 6.00 %) plus a base rate determined by reference to the highest of (a) 0.50 % per annum plus the Federal Funds Effective Rate, (b) the Prime Rate and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month adjusted for certain additional costs, plus 1.00 %; or (2) an applicable margin (equal to 7.00 %) plus LIBOR determined by reference to the cost of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs; provided that such rate is not lower than a floor of 0.50 %. Debt issuance costs related to the term loans are recorded as a direct deduction from the carrying amount of the debt. The balance for debt issuance costs related to the term loans as of October 1, 2022 and January 1, 2022 was $ 34.4 million and $ 37.7 million, respectively. Debt issuance costs related to the Revolving Credit Facility and the undrawn portion of the Delayed Draw Term Loan are recorded within other long-term assets. The balance for debt issuance costs related to the Revolving Credit Facility and the undrawn portion of the Delayed Draw Term Loan as of October 1, 2022 and January 1, 2022 was $ 1.9 million and $ 3.2 million , respectively. The Company recognized interest expense related to the amortization of debt issuance costs of $ 1.6 million and $ 4.9 million during the three and nine-month periods ended October 1, 2022 , respectively, and $ 1.4 million and $ 7.2 million during the three and nine-month periods ended October 2, 2021, respectively. Issued letters of credit as of October 1, 2022 and January 1, 2022 were $ 17.6 million and $ 17.6 million, respectively. There were no swingline loans outstanding as of October 1, 2022 or January 1, 2022 . Borrowing capacity under the Company's Revolving Credit Facility was $ 182.4 million as of October 1, 2022 and January 1, 2022. The fair value of the long-term obligations was $ 1,326.3 million at October 1, 2022. Due to the variable rate nature of the 2021 Extended Term Loan, Delayed Draw Term Loan and Second Lien Term Loan, the Company believes that the carrying amount approximates fair value at October 1, 2022. The Company was in compliance with all financial covenants and restrictions under the foregoing instruments at October 1, 2022 .

Securitization Facility

Securitization Facility	9 Months Ended
	Oct. 01, 2022
Securitization Facility [Abstract]
Securitization Facility	5. SECURITIZATION FACILITY On November 12, 2021, the Company (through a wholly owned special purpose entity, Aveanna SPV I, LLC) (the “special purpose entity”) entered into a Receivables Financing Agreement (as amended, the “Securitization Facility”) with a lending institution with a termination date of November 12, 2024 . On August 9, 2022, the Company amended the Securitization Facility to increase the maximum amount available under the Securitization Facility from $ 150.0 million to $ 175.0 million, subject to certain borrowing base requirements. The Company incurred debt issuance costs of $ 1.4 million in connection with the Securitization Facility, which were capitalized and included in other long-term assets. The Company recognized interest expense related to the amortization of debt issuance costs of $ 0.1 million and $ 0.3 million during the three and nine-month periods ended October 1, 2022, respectively. Pursuant to sale agreements, each of which is among Aveanna Healthcare, LLC, as initial servicer, certain of the Company's subsidiaries and the special purpose entity, the subsidiaries sold substantially all of their existing and future accounts receivable balances to the special purpose entity. The special purpose entity uses the accounts receivable balances to collateralize loans made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty. The outstanding balance under the Securitization Facility was $ 140.0 million and $ 120.0 million at October 1, 2022 and January 1, 2022, respectively. The balance accrues interest at a rate tied to the Bloomberg Short-term Bank Yield Index (“BSBY”) plus an applicable margin, which can increase or decrease based upon the Company's credit rating. The interest rate under the Securitization Facility wa s 5.09 % a nd 2.08 % at October 1, 2022 and January 1, 2022, respectively. The Securitization Facility is accounted for as a collateralized financing activity, rather than a sale of assets, and therefore: (i) accounts receivable balances pledged as collateral are presented as assets and the borrowings are presented as liabilities in the accompanying interim unaudited consolidated balance sheets; (ii) the accompanying interim unaudited consolidated statements of operations reflect the interest expense associated with the collateralized borrowings; and (iii) receipts from customers related to the underlying accounts receivable are reflected as operating cash flows and borrowings and repayments under the collateralized loans are reflected as financing cash flows within the accompanying interim unaudited consolidated statements of cash flows. The Securitization Facility is included within current liabilities on the accompanying interim unaudited consolidated balance sheets as it is collateralized by current patient accounts receivable and not because payments are due within one year of the balance sheet date.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 01, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. FAIR VALUE MEASUREMENTS The carrying amounts of cash and cash equivalents, patient accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair values due to the short-term maturities of the instruments. The Company’s other assets and other liabilities measured at fair value are as follows (amounts in thousands): Fair Value Measurements at October 1, 2022 Level 1 Level 2 Level 3 Total Assets: Interest rate cap agreements $ - $ 49,728 $ - $ 49,728 Interest rate swap agreements - 36,288 - 36,288 Total derivative assets $ - $ 86,016 $ - $ 86,016 Fair Value Measurements at January 1, 2022 Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 15,342 $ - $ 15,342 Total derivative liabilities $ - $ 15,342 $ - $ 15,342 The fair values of the interest rate swap and cap agreements are based on the estimated net proceeds or costs to settle the transactions as of the respective balance sheet dates. The valuations are based on commercially reasonable industry and market practices for valuing similar financial instruments. See Note 7 – Derivative Financial Instruments for further details on the Company’s interest rate swap and cap agreements.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Oct. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	7. DERIVATIVE FINANCIAL INSTRUMENTS The Company’s earnings and cash flows are subject to fluctuations due to changes in interest rates, and the Company seeks to mitigate a portion of this risk by entering into derivative contracts. The derivatives the Company currently uses are interest rate swaps and interest rate caps. The Company recognizes derivatives as either assets or liabilities at fair value on the accompanying interim unaudited consolidated balance sheets and does not designate the derivatives as hedging instruments. Changes in the fair value of derivatives are therefore recorded in earnings throughout the term of the respective derivatives. In October 2018, the Company entered into two interest rate swap agreements to limit its exposure to interest rate risk on its variable rate debt. In July 2021, the Company amended its interest rate swap agreements to extend the expiration dates to June 30, 2026 and reduce the fixed rate paid under the swaps. As amended, the Company pays a fixed rate of 2.08 % and receives the one-month LIBOR rate, subject to a 0.50 % floor. The aggregate notional amount of the interest rate swaps remained unchanged at $ 520.0 million at October 1, 2022 and January 1, 2022, respectively. The fair value of the interest rate swaps at October 1, 2022 and January 1, 2022 was a $ 36.3 million asset included in other long-term assets and a $ 15.3 million liability included in other long-term liabilities on the accompanying interim unaudited consolidated balance sheets, respectively. The Company does not apply hedge accounting to these agreements and records all mark-to-market adjustments directly to other income in the accompanying interim unaudited consolidated statements of operations, which is an adjustment to cash flows from operating activities in the accompanying interim unaudited consolidated financial statement. The net settlements incurred with swap counterparties under the swap agreements prior to the amendment were recognized through cash flows from operating activities in the accompanying interim unaudited consolidated statements of cash flows. Subsequent to the interest rate swap amendment in July 2021, the net settlements are recognized through cash flows from financing activities in the accompanying interim unaudited consolidated statements of cash flows due to an other-than-insignificant financing element on the interest rate swaps resulting from the amendment. On February 9, 2022, the Company entered into interest rate cap agreements for an aggregate notional amount of $ 880.0 million and a cap rate of 3.00 %. The premium paid for the interest rate cap agreements was $ 11.7 million. The cap agreements have an expiration date of February 28, 2027 , and provide that the counterparty will pay the Company the amount by which LIBOR exceeds 3.00 % in a given measurement period. The fair value of the interest rate cap agreements at October 1, 2022 was $ 49.7 million and is included in other long-term assets on the accompanying interim unaudited consolidated balance sheets. The Company does not apply hedge accounting to these agreements and records all mark-to-market adjustments directly to other income in the accompanying interim unaudited consolidated statements of operations, which is an adjustment to cash flows from operating activities in the accompanying interim unaudited consolidated financial statement. The following gains from these derivatives not designated as hedging instruments were recognized in the Company’s accompanying interim unaudited consolidated statements of operations for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively (amounts in thousands): Statement of Operations For the three-month periods ended Classification October 1, 2022 October 2, 2021 Interest rate cap agreement Other income (expense) $ 24,339 $ ( 88 ) Interest rate swap agreements Other income (expense) $ 20,505 $ 1,481 Statement of Operations For the nine-month periods ended Classification October 1, 2022 October 2, 2021 Interest rate cap agreements Other income (expense) $ 38,003 $ ( 88 ) Interest rate swap agreements Other income (expense) $ 51,631 $ 6,334 The Company does not utilize financial instruments for trading or other speculative purposes.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 01, 2022
Income Tax Disclosure [Abstract]
Income Taxes	8. INCOME TAXES The Company’s provision for income taxes is recorded on an interim basis based upon the Company’s estimate of the annual effective income tax rate for the full year applied to “ordinary” income or loss, adjusted each quarter for discrete items. The Company recorded an income tax benefit of $ 2.7 million and $ 0.4 million for the three and nine-month periods ended October 1, 2022, respectively, and income tax benefit of $ 1.1 million and $ 0.6 million for the three and nine-month periods ended October 2, 2021, respectively. The Company’s effective tax rate was negative 12.3 % and 0.1 % for the three and nine-month periods ended October 1, 2022, respectively, and negative 111.1 % and negative 7.2 % for the three and nine-month periods ended October 2, 2021, respectively. The effective tax rates for the three and nine-month periods ended October 1, 2022 and October 2, 2021 differ from the statutory rate of 21 % primarily due to the changes in the valuation allowance recorded against certain deferred tax assets, and separate state and local income taxes on taxable subsidiaries. For the three and nine-month periods ended October 1, 2022, the Company recognized a benefit of approximately $ 2.0 million from the reversal of a previously recognized uncertain tax position. There has been no change to the Company’s policy that recognizes potential interest and penalties related to uncertain tax positions within the Company’s operations in income tax expense in the accompanying interim unaudited consolidated statements of operations.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Oct. 01, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	9. SHARE-BASED COMPENSATION Time-Vesting Options The Company recorded compensation expense, net of forfeitures, of $ 0.2 million and $ 0.9 million for the three and nine-month periods ended October 1, 2022, respectively, an d $ 0.7 million and $ 2.1 million f or the three and nine-month periods ended October 2, 2021, which is included in corporate and branch and regional administrative expenses in the accompanying interim unaudited consolidated statements of operations. Unrecognized compensation expense as of October 1, 2022 associated with outstanding time-vesting options was $ 2.5 million. Performance-Vesting Options The Company recorded compensation expense, net of forfeitures, for the three and nine-month periods ended October 1, 2022 of $ 0.5 million and $ 5.2 million, res pectively, and $ 3.0 million and $ 7.2 million for th e three and nine-month periods ended October 2, 2021, respectively, which is included in corporate and branch and regional administrative expenses in the accompanying interim unaudited consolidated statements of operations. There was no u nrecognized compensation expense as of October 1, 2022 associated with outstanding performance-vesting options. Director Restricted Stock Units The Company recorded compensation expense for the three and nine-month periods ended October 1, 2022 of $ 0.1 million and $ 0.4 million, which is included in corporate expenses in the accompanying interim unaudited consolidated statements of operations. The Company recorded compensation expense of $ 0.2 million for both the three and nine-month periods ended October 2, 2021, which is included in corporate expenses. Unrecognized compensation expense as of October 1, 2022 associated with outstanding director restricted stock units was $ 0.6 million. Management Restricted Stock Units The Company recorded compensation expense for the three and nine-month periods ended October 1, 2022 of $ 1.0 million and $ 3.0 million, which is included in corporate expenses in the accompanying interim unaudited consolidated statements of operations. The Company did no t incur or record any such expense in the three and nine-month periods ended October 2, 2021. Unrecognized compensation expense as of October 1, 2022 associated with outstanding management restricted stock units was $ 12.9 million. Employee Stock Purchase Plan Eligible participants con tributed $ 1.2 million and $ 3.7 million durin g the three and nine-month periods ended October 1, 2022, respectively, which is included in accrued payroll and employee benefits in the accompanying interim unaudited consolidated balance sheets as of October 1, 2022. The Company recorded compensation expense of $ 0.5 million and $ 1.7 million for the three and nine-month periods ended October 1, 2022, respectively, which is included in corporate expenses, branch and regional administrative expenses and cost of revenue, excluding depreciation and amortization in the accompanying interim unaudited consolidated statements of operations. The Company recorded compensation expense of $ 0.3 million asso ciated with the employee stock purchase plan for both the three and nine-month periods ended October 2, 2021. Long-Term Incentive Plan ("LTIP") In the first quarter of 2022, the Compensation Committee of the Company's Board of Directors approved LTIP grants of restricted stock units ("RSUs") and performance stock units ("PSUs") under the Company's 2021 Omnibus Incentive Plan. The RSUs are subject to a three-year service-based cliff vesting schedule commencing on the date of grant. Compensation cost for the RSUs is measured based on the grant date fair value of each share and the number of shares granted and is recognized over the applicable vesting period on a straight-line basis. The Company granted 2,124,212 RSUs with a grant date per share fair value of $ 4.93 . The Company recorded compensation expense, net of forfeitures, of $ 0.8 million and $ 2.1 million during the three and nine-month periods ended October 1, 2022, respectively, which is included in corporate expenses and branch and regional administrative expenses in the accompanying interim unaudited consolidated statements of operations. Unrecognized compensation expense as of October 1, 2022 associated with the remaining RSUs was $ 7.9 million. The PSUs contain two performance criteria: (i) 50% based on relative total shareholder return ("TSR") over a three-year performance period, which measures the Company's total shareholder return as compared to the total shareholder return of a designated peer group, and (ii) 50% based on an adjusted EBITDA target over a one-year performance period. The PSUs are also subject to a three-year service-based cliff vesting schedule commencing on the date of grant. For the PSUs that have a service and a market condition, compensation cost is measured based on the grant date estimated fair value determined using a Monte Carlo simulation model and is recognized over the applicable vesting period on a straight-line basis. The fair value inputs included in the Monte Carlo simulation model were remaining measurement period of 2.88 years, stock price on date of grant of $ 4.93 , daily average closing stock price for the two calendar months prior to the beginning of the performance period of $ 7.29 , risk free rate of 1.77 %, and the performance payout per TSR performance percentile. For the PSUs that have a service and a performance condition, compensation cost is initially measured based on the grant date fair value of each share. Cumulative compensation cost is subsequently adjusted at the end of each reporting period to reflect the current estimation of achieving the performance condition. The Company granted 1,389,801 PSUs with a weighted average grant date per share fair value of $ 5.24 . The Company recorded compensation expense, net of forfeitures, of $ 0.3 million and $ 0.8 million during the three and nine-month periods ended October 1, 2022, respectively, which is included in corporate expenses and branch and regional administrative expenses in the accompanying interim unaudited consolidated statements of operations. Unrecognized compensation expense as of October 1, 2022 associated with the remaining PSUs was $ 3.0 million.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Insurance Reserves As is typical in the healthcare industry, the Company is subject to claims that its services have resulted in patient injury or other adverse effects. The accrued insurance reserves included in the accompanying interim unaudited consolidated balance sheets include estimates of the ultimate costs, including amounts for which the Company's insurance carriers are responsible, for claims that have been reported but not paid and claims that have been incurred but not reported at the balance sheet dates. Although substantially all reported claims are paid directly by the Company’s commercial insurance carriers, the Company is ultimately responsible for payment of these claims in the event its insurance carriers become insolvent or otherwise do not honor the contractual obligations under the related policies. The Company is required under U.S. GAAP to recognize these estimated liabilities in its consolidated financial statements on a gross basis; with a corresponding receivable from the insurance carriers reflecting the contractual indemnity provided by the carriers under the related policies. Effective October 1, 2022, the Company m aintains primary commercial insurance coverage on a claims-made basis for professional malpractice claims with a $ 1.5 million per claim deductible and $ 5.0 million per claim and annual aggregate limits. Prior to October 1, 2022, the Company maintained primary commercial insurance coverage on a claims made basis for professional malpractice claims with varying deductibles by policy year from $ 0.5 million to $ 1.0 million on a per claim basis and $ 5.5 million to $ 6.0 million per claim and annual aggregate limits. Moreover, the Company maintains excess insurance coverage for professional malpractice claims. In addition, the Company maintains workers’ compensation insurance with a $ 0.5 million per claim deductible and statutory limits. The Company reimburses insurance carriers for deductible losses under these policies. The Company’s insurance carriers require collateral to secure the Company’s obligation to reimburse insurance carriers for these deductible payments. Collateral as of October 1, 2022 was comprised of $ 17.6 million of issued letters of credit, $ 2.8 million in cash collateral, and $ 2.9 million in surety bonds. Collateral as of January 1, 2022 was comprised of $ 17.6 million of issued letters of credit, $ 2.9 million in cash collateral, and $ 2.9 million in surety bonds. As of October 1, 2022, insurance reserves totaling $ 85.2 million were included on the accompanying interim unaudited consolidated balance sheets, representing $ 39.1 million and $ 46.1 million of reserves for professional malpractice claims and workers’ compensation claims, respectively. At January 1, 2022, insurance reserves totaling $ 80.5 million were included on the accompanying consolidated balance sheets, representing $ 38.7 million and $ 41.8 million of reserves for professional malpractice claims and workers’ compensation claims, respectively. Litigation and Other Current Liabilities On December 24, 2018, Aveanna Healthcare LLC, an indirect wholly owned subsidiary of the Company, entered into a Stock Purchase Agreement (the “Agreement”) to acquire a pediatric home health company (the “Seller”). The agreement contained a provision whereby a $ 75.0 million transaction termination fee (the “Break-up Fee”) could be payable to the Seller under certain circumstances. On December 20, 2019, Aveanna Healthcare LLC terminated the Agreement, and the Seller demanded payment of the Break-up Fee. The Company believes the Agreement was terminated for cause and therefore no payment of the Break-up Fee is due to the Seller. The Seller has disputed this assertion. While the Company believes that litigation over this matter is unlikely at the present time, it is possible that the Company and the Seller may in the future pursue claims and counterclaims related to the termination of the Agreement and payment of the Break-up Fee. At this time, the Company is unable to predict the possible loss or range of loss, if any, associated with the resolution of any such litigation, or any potential related effect on the Company or its business or operations. On August 6, 2020, the Company sued Epic/Freedom, LLC (“Seller”), Webster Capital Corporation, and Webster Equity Partners (collectively, the “Defendants”) in the Delaware Superior Court. The Company asserted that the Defendants made fraudulent representations and warranties in connection with the Epic acquisition, which closed in March 2017. The Company is seeking damages ranging fro m $ 24.0 million to $ 50.0 million . The Company also requested a declaratory judgment holding that the Defendants waived any claim to the Company’s continued possession of $ 7.1 million in escrow funds (the “Escrow Funds”) that were delivered to the Company in January 2018 by the Epic acquisition escrow agent. In response, the Defendants asserted four counterclaims: (1) specific performance of an alleged right to control a tax audit; (2) advancement of litigation fees and expenses for certain individual Defendants; (3) a declaratory judgment; and (4) breach of contract claim concerning the Escrow Funds. The Company subsequently reached an agreement with the Defendants, which (1) allowed the Defendants to take a principal role in the applicable tax audit, though the Company will continue to communicate with the Internal Revenue Service and retain the ability to make strategic decisions with respect to the audit and (2) dismissed claims against certain individual Defendants mooting Defendants’ claims for advancement of litigation fees and expenses. On July 29, 2021, the Delaware Superior Court denied the Defendants’ motion for judgment on the pleadings with respect to the Company’s claim for fraud against the Defendants, which allows the Company to pursue discovery with respect to the alleged fraud claim. With respect to the Company’s retention of certain tax refunds the Company received on behalf of Defendants, the Court denied the Company’s motion for judgment on the pleadings, pursuant to which the Company sought to retain the tax refunds as matter of law. The Court also ordered Seller to refile its motion for summary judgment on the same subject and abated a ruling pending further discovery and resolution of whether the parties entered into a post-closing agreement, allowing the Company to retain the tax refunds pending the outcome of the related tax audits. Lastly, the Court denied the Company’s motion for judgment on the pleadings as to its continued possession of the Escrow Funds. At this time, the Company cannot predict the ultimate resolution or estimate the amount of any loss or recovery, if any, related to this matter. The Company is currently a party to various routine litigation incidental to the business. While management currently believes that the ultimate outcome of such proceedings, individually and in the aggregate, will not have a material adverse effect on the Company’s financial position or overall trends in results of operations, litigation is subject to inherent uncertainties. Management has established provisions within other current liabilities in the accompanying interim unaudited consolidated balance sheets, which in the opinion of management represents the best estimate of exposure and adequately provides for such losses that may occur from asserted claims related to the provision of professional services and which may not be covered by the Company’s insurance policies. Management believes that any additional unfavorable provisions would not be material to the Company’s results of operations or financial position; however, if an unfavorable ruling on any asserted or unasserted claim were to occur, there exists the possibility of a material adverse impact on the Company’s net earnings or financial position. The estimate of the potential impact from legal proceedings on the Company’s financial position or overall results of operations could change in the future. Healthcare Regulatory Matters Starting on October 30, 2019 the Company has received grand jury subpoenas issued by the U.S. Department of Justice, Antitrust Division (the “Antitrust Division”) requiring the production of documents and information pertaining to nurse wages, reimbursement rates, and hiring activities in a few of its local markets. The Company is fully cooperating with the Antitrust Division with respect to this investigation and management believes that it is not probable that this matter will materially impact the Company’s business, results of operations or financial condition. However, based on the information currently available to the Company, management cannot predict the timing or outcome of this investigation or predict the possible loss or range of loss, if any, associated with the resolution of this litigation. Laws and regulations governing the government payer programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation as well as significant regulatory action. From time to time, governmental regulatory agencies conduct inquiries and audits of the Company’s practices. It is the Company’s practice to cooperate fully with such inquiries. In addition to laws and regulations governing the Medicaid, Medicaid Managed Care, and Tricare programs, there are a number of federal and state laws and regulations governing matters such as the corporate practice of medicine, fee splitting arrangements, anti-kickback statues, physician self-referral laws, false or fraudulent claims filing and patient privacy requirements. Failure to comply with any such laws or regulations could have an adverse impact on the Company’s operations and financial results. The Company believes that it is in material compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of wrongdoing.

Covid-19

Covid-19	9 Months Ended
	Oct. 01, 2022
Covid19 C A R E S Act [Abstract]
Covid-19	11. COVID-19 In March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 outbreak has adversely impacted economic activity and conditions worldwide, including workforces, liquidity, capital markets, consumer behavior, supply chains and macroeconomic conditions. After the declaration of a national emergency in the United States on March 13, 2020, in compliance with stay-at-home and physical distancing orders and other restrictions on movement and economic activity intended to reduce the spread of COVID-19, the Company altered numerous clinical, operational, and business processes. While each of the states deemed healthcare services an essential business, allowing the Company to continue to deliver healthcare services to patients, the effects of the pandemic have been wide-reaching. In response to COVID-19, the U.S. Government enacted the CARES Act on March 27, 2020. The CARES Act has impacted the Company as follows: Provider Relief Fund (“PRF”) : Beginning in April 2020, funds were distributed to health care providers who provide or provided diagnoses, testing, or care for individuals with possible or actual cases of COVID-19. In fiscal year 2020, the Company received PRF payments from the U.S. Department of Health and Human Services (“HHS”) totaling $ 25.1 million. On March 5, 2021, the Company repaid these PRF payments in full. In December 2021, the Company also received PRF payments from HHS totaling $ 2.5 million. The Company repaid these PRF payments in full in December 2021. State Sponsored Relief Funds : In fiscal year 2020, the Company received $ 4.8 million of stimulus funds from the Commonwealth of Pennsylvania Department of Human Services (“Pennsylvania DHS”). Such funds were not applied for or requested. The Company did no t receive stimulus funds from any individual state other than Pennsylvania. The Company previously recognized $ 0.5 million of income related to these funds in fiscal year 2020. On February 4, 2021, the Company repaid the remaining $ 4.3 million of direct stimulus funds to Pennsylvania DHS. Deferred payment of the employer portion of social security taxes : The Company was permitted to defer payments of the employer portion of social security taxes in fiscal year 2020, which are payable in 50 % increments, with the first 50 % due by December 31, 2021 and the second 50 % due by December 31, 2022. The Company did not defer any payroll taxes after December 31, 2020. As of October 1, 2022 and January 1, 2022, the Company had remaining deferred payments of $ 25.5 million of social security taxes in total, which is recorded in the current portion of deferred payroll taxes on the accompanying interim unaudited consolidated balance sheets. Medicare Advances : Certain of the home health and hospice companies the Company has acquired received advance payments from the Centers for Medicare & Medicaid Services (“CMS”) in April 2020, pursuant to the expansion of the Accelerated Payments Program provided for in the CARES Act. These advances became repayable beginning one year from the date on which the accelerated advance was issued. The repayments occur via offsets by CMS to current payments otherwise due from Medicare at a rate of 25 % for the first eleven months. After the eleven months end, payments will be recouped at a rate of 50 % for another six months, after which any remaining balance will become due. Gross advances received by acquired companies in April 2020 totaled $ 15.7 million. The Company began repaying the gross amount of the advances, via the offset mechanism described above, during the second quarter of fiscal year 2021, and had repaid all such advances as of July 2, 2022. Temporary Suspension of Medicare Sequestration: The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare fee-for-service claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0 % reduction in Medicare payments. All Medicare rate payments and settlements are subject to this mandatory reduction, which will continue to remain in place through at least 2023, unless Congress takes further action. In response to COVID-19, the CARES Act temporarily suspended the automatic 2.0 % reduction of Medicare claim reimbursements for the period from May 1, 2020 through December 31, 2021. In December 2021, Congress extended the suspension of the automatic 2.0 % reduction through March 2022 and reduced the sequestration adjustment to 1.0 % from April 1, 2022 through June 30, 2022, with the full 2.0 % reduction for sequestration resuming thereafter. American Rescue Plan Act (“ARPA”): On March 11, 2021 President Biden signed ARPA into law. ARPA is a federal stimulus bill designed to aid public health and economic recovery from the COVID-19 pandemic. ARPA includes $ 350 billion in emergency funding for state, local, territorial and tribal governments, known as the Coronavirus State and Local Fiscal Recovery Funds (“ARPA Recovery Funds”). States must obligate the ARPA Recovery Funds by December 31, 2024 and spend such funds by December 31, 2026. Usage of the ARPA Recovery Funds is subject to the requirements specified in the United States Treasury Department’s Final Rule issued on January 6, 2022. The Final Rule provides states with substantial flexibility in utilizing ARPA Relief Funds, including to support public health expenditures such as vaccination programs and testing, and PPE purchases, as well as providing premium pay for essential workers, including those in home-care settings, among many other things. States may not use ARPA Recovery Funds to fund tax cuts, fund budget deficits, or to support public employee pensions. During the three and nine-month periods ended October 1, 2022, the Company rece ived $ 1.0 million and $ 5.5 million, respectively, of ARPA Recovery Funds from various states. The Company recognized $ 1.4 million and $ 5.0 mil lion during the three and nine-month periods ended October 1, 2022, respectively, as revenue in our accompanying interim unaudited consolidated statements of operations. The remaining ARPA Recovery Funds are recorded in other current liabilities in the accompanying interim unaudited consolidated balance sheet at October 1, 2022.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Oct. 01, 2022
Related Party Transactions [Abstract]
Related Party Transactions	12. RELATED PARTY TRANSACTIONS The Company was a party to an advisory services agreement with affiliates of certain stockholders of the Company (the “Management Agreement”). Under this agreement, the managers provided general and strategic advisory services and were paid a quarterly management fee plus out of pocket expenses. Upon completion of the Company's initial public offering in April 2021 (the "IPO"), the Management Agreement was terminated. Additionally, the managers agreed to waive the fee due to them from the Company upon the successful completion of the IPO. The Company did no t incur any management fees or expenses during the three or nine-month period ended October 1, 2022 or the three-month period ended October 2, 2021. The Company incurred management fees and expenses of $ 0.9 million during the nine-month period ended October 2, 2021, which is included in corporate expenses in the accompanying interim unaudited consolidated statements of operations. The Company did no t owe any amounts in connection with the Management Agreement as of October 1, 2022 or January 1, 2022. As of October 1, 2022, one of the Company’s stockholders owned 6.8 % of the Company’s 2021 Extended Term Loan.

Segment Information

Segment Information	9 Months Ended
	Oct. 01, 2022
Segment Reporting [Abstract]
Segment Information	13. SEGMENT INFORMATION The Company’s operating segments have been identified based upon how management has organized the business by services provided to customers and how the chief operating decision maker (“CODM”) manages the business and allocates resources. The Company has three operating segments and three reportable segments, Private Duty Services, Home Health & Hospice, and Medical Solutions. The PDS segment predominantly includes private duty skilled nursing services, unskilled and personal care services, and pediatric therapy services. The HHH segment provides home health and hospice services to predominately elderly patients. Through the MS segment, the Company provides enteral nutrition and other products to adults and children, delivered on a periodic or as-needed basis. The CODM evaluates performance using gross margin (and gross margin percentage). Gross margin includes revenue less all costs of revenue, excluding depreciation and amortization, but excludes branch and regional administrative expenses, corporate expenses and other non-field expenses. The CODM does not evaluate a measure of assets when assessing performance. Results shown for the three and nine-month periods ended October 1, 2022 and October 2, 2021 are not necessarily those which would be achieved if each segment was an unaffiliated business enterprise. There are no intersegment transactions. The following tables summarize the Company’s segment information for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively (amounts in thousands): For the three-month period ended October 1, 2022 PDS HHH MS Total Revenue $ 355,620 $ 49,853 $ 37,536 $ 443,009 Cost of revenue, excluding depreciation and amortization 254,756 32,968 20,702 308,426 Gross margin $ 100,864 $ 16,885 $ 16,834 $ 134,583 Gross margin percentage 28.4 % 33.9 % 44.8 % 30.4 % For the three-month period ended October 2, 2021 PDS HHH MS Total Revenue $ 327,133 $ 47,000 $ 37,143 $ 411,276 Cost of revenue, excluding depreciation and amortization 226,540 24,130 $ 20,864 271,534 Gross margin $ 100,593 $ 22,870 $ 16,279 $ 139,742 Gross margin percentage 30.7 % 48.7 % 43.8 % 34.0 % For the nine-month period ended October 1, 2022 PDS HHH MS Total Revenue $ 1,053,835 $ 177,858 $ 104,805 $ 1,336,498 Cost of revenue, excluding depreciation and amortization 753,266 98,933 59,847 912,046 Gross margin $ 300,569 $ 78,925 $ 44,958 $ 424,452 Gross margin percentage 28.5 % 44.4 % 42.9 % 31.8 % For the nine-month period ended October 2, 2021 PDS HHH MS Total Revenue $ 1,027,640 $ 128,589 $ 108,319 $ 1,264,548 Cost of revenue, excluding depreciation and amortization 719,435 67,224 59,875 846,534 Gross margin $ 308,205 $ 61,365 $ 48,444 $ 418,014 Gross margin percentage 30.0 % 47.7 % 44.7 % 33.1 % For the three-month periods ended For the nine-month periods ended Segment Reconciliation: October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Total segment gross margin $ 134,583 $ 139,742 $ 424,452 $ 418,014 Branch and regional administrative expenses 89,542 76,370 267,283 223,462 Corporate expenses 33,215 37,873 105,984 97,673 Goodwill impairment - - 470,207 - Depreciation and amortization 4,917 5,145 16,774 15,163 Acquisition-related costs - 2,007 69 4,779 Other operating expense 2,122 - 1,953 - Operating income (loss) 4,787 18,347 ( 437,818 ) 76,937 Interest income 164 44 369 182 Interest expense ( 28,462 ) ( 12,106 ) ( 73,745 ) ( 53,793 ) Loss on debt extinguishment - ( 4,784 ) - ( 13,702 ) Other income (expense) 45,140 ( 511 ) 86,523 ( 1,088 ) Income (Loss) before income taxes $ 21,629 $ 990 $ ( 424,671 ) $ 8,536

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Oct. 01, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	14. NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the diluted weighted average number of shares of common stock outstanding for the period. For purposes of this calculation, outstanding stock options are considered potential dilutive shares of common stock. The following is a computation of basic and diluted net income (loss) per share (amounts in thousands, except per share amounts): For the three-month periods ended For the nine-month periods ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Numerator: Net income (loss) $ 24,298 $ 2,090 $ ( 424,255 ) $ 9,148 Denominator: Weighted average shares of common stock outstanding (1) , basic 186,113 184,554 185,327 165,877 Net income (loss) per share, basic $ 0.13 $ 0.01 $ ( 2.29 ) $ 0.06 Weighted average shares of common stock outstanding (1) , diluted 186,166 188,246 185,327 170,667 Net income (loss) per share, diluted $ 0.13 $ 0.01 $ ( 2.29 ) $ 0.05 Dilutive securities outstanding not included in the computation of diluted net income (loss) per share as their effect is antidilutive: RSUs 4,684 - 4,722 - PSUs 1,368 - 1,368 - Stock options 14,553 6,885 14,553 6,360 (1) The calculation of weighted average shares of common stock outstanding includes all vested deferred restricted stock units.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying interim unaudited consolidated financial statements include the accounts of Aveanna Healthcare Holdings Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in the accompanying interim unaudited consolidated financial statements, and business combinations accounted for as purchases have been included in the accompanying interim unaudited consolidated financial statements from their respective dates of acquisition.
Basis of Presentation	Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these interim unaudited consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, these interim unaudited consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the Company’s financial position as of October 1, 2022 and the results of operations for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively. The results reported in these interim unaudited consolidated financial statements should not be regarded as indicative of results that may be expected for any other period or the entire year. These interim unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes for the fiscal year ended January 1, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 28, 2022. Our fiscal year ends on the Saturday that is closest to December 31 of a given year, resulting in either a 52 or 53-week fiscal year. The accompanying interim unaudited consolidated balance sheets reflect the accounts of the Company as of October 1, 2022 and January 1, 2022. For the three-month periods ended October 1, 2022 and October 2, 2021, the accompanying interim unaudited consolidated statements of operations, stockholders’ equity and cash flows reflect the accounts of the Company from July 2, 2022 through October 1, 2022 and July 3, 2021 through October 2, 2021, respectively. For the nine-month periods ended October 1, 2022 and October 2, 2021, the accompanying interim unaudited consolidated statements of operations, stockholders' equity and cash flows reflect the accounts of the Company from January 2, 2022 through October 1, 2022 and January 3, 2021 through October 2, 2021 , respectively.
Use of Estimates	Use of Estimates The Company’s accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, the Company is required to make estimates and assumptions that impact the amounts reported in these consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. An entity may adopt this ASU as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the impact of adopting this standard. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope , to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. This ASU is effective immediately and should be adopted in conjunction with ASU 2020-04. The Company is currently evaluating the impact of adopting this standard.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Oct. 01, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Payer Type as a Percentage of Revenue	The following table presents revenue by payer type as a percentage of revenue for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively: For the three-month periods ended For the nine-month periods ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Percentage Percentage Percentage Percentage Medicaid MCO 50.9 % 53.3 % 51.6 % 53.9 % Medicaid 21.6 % 24.6 % 21.8 % 24.4 % Commercial 8.4 % 9.7 % 9.4 % 11.1 % Medicare 19.0 % 12.1 % 17.1 % 10.3 % Self-pay 0.1 % 0.3 % 0.1 % 0.3 % Total revenue 100.0 % 100.0 % 100.0 % 100.0 %

Long-Term Obligations (Tables)

Long-Term Obligations (Tables)	9 Months Ended
	Oct. 01, 2022
Debt Disclosure [Abstract]
Schedule of Long-Term Obligations	Long-term obligations consisted of the following as of October 1, 2022 and January 1, 2022, respectively (dollar amounts in thousands): Instrument Stated Contractual Interest Rate Interest Rate October 1, 2022 January 1, 2022 2021 Extended Term Loan (1) 07/2028 L + 3.75 % 6.89 % $ 851,400 $ 857,850 Delayed Draw Term Loan (1) 07/2028 L + 3.75 % 6.89 % 59,850 - Second Lien Term Loan (1) 12/2029 L + 7.00 % 10.14 % 415,000 415,000 Revolving Credit Facility (1) 04/2026 L + 3.75 % 6.89 % - - Total principal amount of long-term obligations 1,326,250 1,272,850 Less: unamortized debt issuance costs ( 34,447 ) ( 37,733 ) Total amount of long-term obligations, net of unamortized debt issuance costs 1,291,803 1,235,117 Less: current portion of long-term obligations ( 9,200 ) ( 8,600 ) Total amount of long-term obligations, net of unamortized debt issuance costs, less current portion $ 1,282,603 $ 1,226,517 (1) L = Greater of 0.50% or one-month LIBOR

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 01, 2022
Fair Value Disclosures [Abstract]
Summary of Other Assets and Other Liabilities Measured at Fair Value	The Company’s other assets and other liabilities measured at fair value are as follows (amounts in thousands): Fair Value Measurements at October 1, 2022 Level 1 Level 2 Level 3 Total Assets: Interest rate cap agreements $ - $ 49,728 $ - $ 49,728 Interest rate swap agreements - 36,288 - 36,288 Total derivative assets $ - $ 86,016 $ - $ 86,016 Fair Value Measurements at January 1, 2022 Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 15,342 $ - $ 15,342 Total derivative liabilities $ - $ 15,342 $ - $ 15,342

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Oct. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Gains from Derivatives	The following gains from these derivatives not designated as hedging instruments were recognized in the Company’s accompanying interim unaudited consolidated statements of operations for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively (amounts in thousands): Statement of Operations For the three-month periods ended Classification October 1, 2022 October 2, 2021 Interest rate cap agreement Other income (expense) $ 24,339 $ ( 88 ) Interest rate swap agreements Other income (expense) $ 20,505 $ 1,481 Statement of Operations For the nine-month periods ended Classification October 1, 2022 October 2, 2021 Interest rate cap agreements Other income (expense) $ 38,003 $ ( 88 ) Interest rate swap agreements Other income (expense) $ 51,631 $ 6,334

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Oct. 01, 2022
Segment Reporting [Abstract]
Summary of Segment Information	The following tables summarize the Company’s segment information for the three and nine-month periods ended October 1, 2022 and October 2, 2021, respectively (amounts in thousands): For the three-month period ended October 1, 2022 PDS HHH MS Total Revenue $ 355,620 $ 49,853 $ 37,536 $ 443,009 Cost of revenue, excluding depreciation and amortization 254,756 32,968 20,702 308,426 Gross margin $ 100,864 $ 16,885 $ 16,834 $ 134,583 Gross margin percentage 28.4 % 33.9 % 44.8 % 30.4 % For the three-month period ended October 2, 2021 PDS HHH MS Total Revenue $ 327,133 $ 47,000 $ 37,143 $ 411,276 Cost of revenue, excluding depreciation and amortization 226,540 24,130 $ 20,864 271,534 Gross margin $ 100,593 $ 22,870 $ 16,279 $ 139,742 Gross margin percentage 30.7 % 48.7 % 43.8 % 34.0 % For the nine-month period ended October 1, 2022 PDS HHH MS Total Revenue $ 1,053,835 $ 177,858 $ 104,805 $ 1,336,498 Cost of revenue, excluding depreciation and amortization 753,266 98,933 59,847 912,046 Gross margin $ 300,569 $ 78,925 $ 44,958 $ 424,452 Gross margin percentage 28.5 % 44.4 % 42.9 % 31.8 % For the nine-month period ended October 2, 2021 PDS HHH MS Total Revenue $ 1,027,640 $ 128,589 $ 108,319 $ 1,264,548 Cost of revenue, excluding depreciation and amortization 719,435 67,224 59,875 846,534 Gross margin $ 308,205 $ 61,365 $ 48,444 $ 418,014 Gross margin percentage 30.0 % 47.7 % 44.7 % 33.1 % For the three-month periods ended For the nine-month periods ended Segment Reconciliation: October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Total segment gross margin $ 134,583 $ 139,742 $ 424,452 $ 418,014 Branch and regional administrative expenses 89,542 76,370 267,283 223,462 Corporate expenses 33,215 37,873 105,984 97,673 Goodwill impairment - - 470,207 - Depreciation and amortization 4,917 5,145 16,774 15,163 Acquisition-related costs - 2,007 69 4,779 Other operating expense 2,122 - 1,953 - Operating income (loss) 4,787 18,347 ( 437,818 ) 76,937 Interest income 164 44 369 182 Interest expense ( 28,462 ) ( 12,106 ) ( 73,745 ) ( 53,793 ) Loss on debt extinguishment - ( 4,784 ) - ( 13,702 ) Other income (expense) 45,140 ( 511 ) 86,523 ( 1,088 ) Income (Loss) before income taxes $ 21,629 $ 990 $ ( 424,671 ) $ 8,536

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Oct. 01, 2022
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	The following is a computation of basic and diluted net income (loss) per share (amounts in thousands, except per share amounts): For the three-month periods ended For the nine-month periods ended October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Numerator: Net income (loss) $ 24,298 $ 2,090 $ ( 424,255 ) $ 9,148 Denominator: Weighted average shares of common stock outstanding (1) , basic 186,113 184,554 185,327 165,877 Net income (loss) per share, basic $ 0.13 $ 0.01 $ ( 2.29 ) $ 0.06 Weighted average shares of common stock outstanding (1) , diluted 186,166 188,246 185,327 170,667 Net income (loss) per share, diluted $ 0.13 $ 0.01 $ ( 2.29 ) $ 0.05 Dilutive securities outstanding not included in the computation of diluted net income (loss) per share as their effect is antidilutive: RSUs 4,684 - 4,722 - PSUs 1,368 - 1,368 - Stock options 14,553 6,885 14,553 6,360 (1) The calculation of weighted average shares of common stock outstanding includes all vested deferred restricted stock units.

Description of Business - Addit

Description of Business - Additional Information (Details)	Oct. 01, 2022 State
Subsidiary, Sale of Stock [Line Items]
Number of states in which entity locations	33

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Jan. 01, 2022
Revenue Disclosure [Line Items]
Estimated price concession	$ 62,200,000		$ 62,200,000		$ 55,800,000
Bad debt expense	$ 0	$ 0	$ 0	$ 0
Maximum
Revenue Disclosure [Line Items]
Revenue, performance obligation, expected timing of satisfaction, period	1 year		1 year

Revenue - Schedule of Revenue b

Revenue - Schedule of Revenue by Payer Type as a Percentage of Revenue (Detail) - Customer Concentration Risk - Total revenue	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Disaggregation Of Revenue [Line Items]
Percentage of total revenue	100%	100%	100%	100%
Medicaid MCO
Disaggregation Of Revenue [Line Items]
Percentage of total revenue	50.90%	53.30%	51.60%	53.90%
Medicaid
Disaggregation Of Revenue [Line Items]
Percentage of total revenue	21.60%	24.60%	21.80%	24.40%
Commercial
Disaggregation Of Revenue [Line Items]
Percentage of total revenue	8.40%	9.70%	9.40%	11.10%
Medicare
Disaggregation Of Revenue [Line Items]
Percentage of total revenue	19%	12.10%	17.10%	10.30%
Self-pay
Disaggregation Of Revenue [Line Items]
Percentage of total revenue	0.10%	0.30%	0.10%	0.30%

Long-Term Obligations - Schedul

Long-Term Obligations - Schedule of Long-Term Obligations and Notes Payable (Details) - USD ($) $ in Thousands		9 Months Ended
	Dec. 10, 2021	Oct. 01, 2022	Jan. 01, 2022
Debt Instrument [Line Items]
Total principal amount of long-term obligations		$ 1,326,250	$ 1,272,850
Less: unamortized debt issuance costs		(34,447)	(37,733)
Total amount of long-term obligations, net of unamortized debt issuance costs		1,291,803	1,235,117
Less: current portion of long-term obligations		(9,200)	(8,600)
Total amount of long-term obligations, net of unamortized debt issuance costs, less current portion		1,282,603	1,226,517
2021 Extended Term Loan
Debt Instrument [Line Items]
Total principal amount of long-term obligations		$ 851,400	857,850
Stated Maturity Date		2028-07
Contractual Interest Rate		L + 3.75%
Interest Rate		6.89%
2021 Extended Term Loan | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings		3.75%
Second Lien Term Loan
Debt Instrument [Line Items]
Total principal amount of long-term obligations		$ 415,000	$ 415,000
Stated Maturity Date		2029-12
Contractual Interest Rate		L + 7.00%
Interest Rate		10.14%
Second Lien Term Loan | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings	7%	7%
Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Total principal amount of long-term obligations		$ 59,850
Stated Maturity Date		2028-07
Contractual Interest Rate		L + 3.75%
Interest Rate		6.89%
Delayed Draw Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings		3.75%
Revolving Credit Facility
Debt Instrument [Line Items]
Stated Maturity Date		2026-04
Contractual Interest Rate		L + 3.75%
Interest Rate		6.89%
Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings		3.75%

Long-Term Obligations - Sched_2

Long-Term Obligations - Schedule of Long-Term Obligations and Notes Payable (Parenthetical) (Details)	9 Months Ended
	Oct. 01, 2022
Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, description of contractual interest rate	L = Greater of 0.50% or one-month LIBOR
Second Lien Term Loan
Debt Instrument [Line Items]
Debt instrument, description of contractual interest rate	L = Greater of 0.50% or one-month LIBOR
2021 Extended Term Loan
Debt Instrument [Line Items]
Debt instrument, description of contractual interest rate	L = Greater of 0.50% or one-month LIBOR
Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, description of contractual interest rate	L = Greater of 0.50% or one-month LIBOR

Long-Term Obligations - Additio

Long-Term Obligations - Additional Information (Details) - USD ($)				3 Months Ended		9 Months Ended
	Aug. 09, 2022	Dec. 10, 2021	Jul. 15, 2021	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Jan. 01, 2022
Debt Instrument [Line Items]
Debt issuance costs				$ 34,447,000		$ 34,447,000		$ 37,733,000
Interest expense related to amortization of debt issuance costs				1,600,000	$ 1,400,000	4,900,000	$ 7,200,000
Swingline loans				0		0		0
Fair value of long-term obligations				1,326,300,000		1,326,300,000
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				182,400,000		$ 182,400,000		182,400,000
Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings						3.75%
Letter of Credit
Debt Instrument [Line Items]
Issued letter of credit				17,600,000		$ 17,600,000		17,600,000
Term Loan
Debt Instrument [Line Items]
Debt issuance costs				34,400,000		$ 34,400,000		37,700,000
Second Lien Term Loan
Debt Instrument [Line Items]
Debt instrument minimum floor rate percentage		0.50%
Second Lien Term Loan | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings		7%				7%
Second Lien Term Loan | Annual Base Rate
Debt Instrument [Line Items]
Interest rate margin on borrowings		6%
Second Lien Term Loan | Federal Funds Effective Rate
Debt Instrument [Line Items]
Interest rate margin on borrowings		0.50%
Second Lien Term Loan | One Month LIBOR Rate
Debt Instrument [Line Items]
Interest rate margin on borrowings		1%
2021 Extended Term Loan | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings						3.75%
Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Debt issuance costs				$ 1,900,000		$ 1,900,000		$ 3,200,000
Amount borrowed	$ 60,000,000
Amount of remaining available borrowing	$ 140,000,000
Delayed Draw Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Interest rate margin on borrowings						3.75%
2021 Extended Term Loan and Delayed Draw Term Loans | LIBOR | Minimum
Debt Instrument [Line Items]
Debt instruments, variable interest rate			0.50%
2021 Extended Term Loan and Delayed Draw Term Loans | LIBOR | Maximum
Debt Instrument [Line Items]
Interest rate margin on borrowings			3.75%
2021 Extended Term Loan and Delayed Draw Term Loans | Annual Base Rate | Minimum
Debt Instrument [Line Items]
Debt instruments, variable interest rate			2%
Interest rate margin on borrowings			2.75%

Securitization Facility - Addit

Securitization Facility - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 12, 2021	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Jan. 01, 2022	Aug. 09, 2022
Debt Instrument [Line Items]
Outstanding balance		$ 1,326,250		$ 1,326,250		$ 1,272,850
Interest expense related to amortization of debt issuance costs		1,600	$ 1,400	4,900	$ 7,200
Securitization Facility
Debt Instrument [Line Items]
Termination date of agreement	Nov. 12, 2024
Maximum amount available under securitization facility	$ 150,000						$ 175,000
Debt issuance costs	$ 1,400
Outstanding balance		140,000		140,000		$ 120,000
Interest expense related to amortization of debt issuance costs		$ 100		$ 300
Securitization Facility | Bloomberg Short-term Bank Yield Index
Debt Instrument [Line Items]
Interest rate under facility				5.09%		2.08%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Other Assets and Other Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Oct. 01, 2022	Jan. 01, 2022
Assets:
Total derivative assets	$ 86,016
Liabilities:
Total derivative liabilities		$ 15,342
Level 2
Assets:
Total derivative assets	86,016
Liabilities:
Total derivative liabilities		15,342
Interest Rate Cap Agreement
Assets:
Total derivative assets	49,728
Interest Rate Cap Agreement | Level 2
Assets:
Total derivative assets	49,728
Interest Rate Swap Agreements
Assets:
Total derivative assets	36,288
Liabilities:
Total derivative liabilities		15,342
Interest Rate Swap Agreements | Level 2
Assets:
Total derivative assets	$ 36,288
Liabilities:
Total derivative liabilities		$ 15,342

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Details)		1 Months Ended
	Feb. 09, 2022 USD ($)	Jul. 31, 2021	Oct. 01, 2022 USD ($)	Jan. 01, 2022 USD ($)	Oct. 31, 2018 Swap
Other Long-Term Assets
Derivative [Line Items]
Fair value of interest rate swaps			$ 36,300,000
Other Long-Term Liabilities
Derivative [Line Items]
Fair value of interest rate swaps				$ 15,300,000
Amended Interest Rate Swap Agreements
Derivative [Line Items]
Aggregate notional amount			520,000,000	$ 520,000,000
Derivative expiration date		Jun. 30, 2026
Derivative, fixed interest rate		2.08%
Derivative, floor interest rate		0.50%
Interest Rate Swap Agreement
Derivative [Line Items]
Number of interest rate swap agreement | Swap					2
Interest Rate Cap Agreement
Derivative [Line Items]
Aggregate notional amount	$ 880,000,000
Fair value of interest rate swaps			$ 49,700,000
Derivative expiration date	Feb. 28, 2027
Derivative, cap interest rate	3%
One-time premium paid	$ 11,700,000

Derivative Financial Instrume_4

Derivative Financial Instruments - Schedule of Gains from Derivatives (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Derivative Instruments Gain Loss [Line Items]
Derivative gain (loss)			$ 89,634	$ 6,246
Interest Rate Cap Agreement | Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Derivative gain (loss)	$ 24,339	$ (88)	$ 38,003	$ (88)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Interest Rate Swap Agreements | Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Derivative gain (loss)	$ 20,505	$ 1,481	$ 51,631	$ 6,334
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (2,669)	$ (1,100)	$ (416)	$ (612)
Effective tax rate	(12.30%)	(111.10%)	0.10%	(7.20%)
Statutory tax rate	21%	21%	21%	21%
Recognized tax benefits	$ 2,000		$ 2,000

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Time Vesting Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense, net of forfeitures	$ 200,000	$ 700,000	$ 900,000	$ 2,100,000
Unrecognized compensation expense	2,500,000		2,500,000
Performance-Vesting Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense, net of forfeitures	500,000	3,000,000	5,200,000	7,200,000
Unrecognized compensation expense	0		0
Restricted Stock Units | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	100,000	200,000	400,000	200,000
Unrecognized compensation expense	600,000		600,000
Restricted Stock Units | Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	1,000,000	0	3,000,000	0
Unrecognized compensation expense	12,900,000		12,900,000
Long-Term Incentive Plan | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense, net of forfeitures	800,000		2,100,000
Unrecognized compensation expense	7,900,000		$ 7,900,000
Shares granted			2,124,212
Fair value of shares granted			$ 4.93
Long-Term Incentive Plan | Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense, net of forfeitures	300,000		$ 800,000
Unrecognized compensation expense	$ 3,000,000		$ 3,000,000
Shares granted			1,389,801
Fair value of shares granted			$ 5.24
Term of award			The PSUs contain two performance criteria: (i) 50% based on relative total shareholder return ("TSR") over a three-year performance period, which measures the Company's total shareholder return as compared to the total shareholder return of a designated peer group, and (ii) 50% based on an adjusted EBITDA target over a one-year performance period. The PSUs are also subject to a three-year service-based cliff vesting schedule commencing on the date of grant.
Fair value of shares remaining measurement period			2 years 10 months 17 days
Share price	$ 4.93		$ 4.93
Risk-free interest rate			1.77%
Average closing stock price			7.29
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense		300,000		300,000
Cash contribution to plan	$ 1,200,000		$ 3,700,000
Employee Stock Purchase Plan | Corporate Expenses and Branch and Regional Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense		$ 500,000		$ 1,700,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)				9 Months Ended
	Oct. 01, 2022	Sep. 30, 2022	Aug. 06, 2020	Oct. 01, 2022	Jan. 01, 2022	Dec. 20, 2019	Dec. 24, 2018
Loss Contingencies [Line Items]
Insurance, per claims deductible	$ 1,500,000
Professional malpractice claims, per claim and annual aggregate limits	5,000,000
Insurance reserves	85,200,000			$ 85,200,000	$ 80,500,000
Provision for transaction termination fee							$ 75,000,000
Break-up fee due to Seller						$ 0
Escrow funds			$ 7,100,000
Name of defendants				Epic/Freedom, LLC (“Seller”), Webster Capital Corporation, and Webster Equity Partners (collectively, the “Defendants”)
Minimum
Loss Contingencies [Line Items]
Insurance, per claims deductible		$ 500,000
Professional malpractice claims, per claim and annual aggregate limits		5,500,000
Damages sought value			24,000,000
Maximum
Loss Contingencies [Line Items]
Insurance, per claims deductible		1,000,000
Professional malpractice claims, per claim and annual aggregate limits		$ 6,000,000
Damages sought value			$ 50,000,000
Professional Malpractice Claims
Loss Contingencies [Line Items]
Insurance reserves	39,100,000			$ 39,100,000	38,700,000
Surety Bonds
Loss Contingencies [Line Items]
Collaterals	2,900,000			2,900,000	2,900,000
Cash Collateral
Loss Contingencies [Line Items]
Collaterals	2,800,000			2,800,000	2,900,000
Letters of Credit
Loss Contingencies [Line Items]
Collaterals	17,600,000			17,600,000	17,600,000
Workers Compensation Insurance
Loss Contingencies [Line Items]
Insurance, per claims deductible				500,000
Insurance reserves	$ 46,100,000			$ 46,100,000	$ 41,800,000

Covid-19 - Additional Informati

Covid-19 - Additional Information (Detail) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

4 Months Ended

9 Months Ended

12 Months Ended

20 Months Ended

Jul. 01, 2022

Mar. 11, 2021

Dec. 31, 2021

Oct. 01, 2022

Jun. 30, 2022

Mar. 31, 2022

Oct. 01, 2022

Jan. 02, 2021

Dec. 31, 2021

Dec. 31, 2022

Jan. 01, 2022

Feb. 04, 2021

Apr. 30, 2020

Apr. 01, 2013

Covid 19 CARES Act [Line Items]

Provider relief fund payments received CARES Act

$ 2,500

$ 25,100

Incremental percentage of deferred payment of employer portion of social security taxes

50%

Percentage of social security tax due CARES Act

50%

50%

50%

Deferred social security tax CARES Act

$ 25,500

$ 25,500

$ 25,500

ARPA Recovery Funds

$ 350,000,000

1,000

5,500

Revenue recognized

$ 1,400

$ 5,000

Medicare

Covid 19 CARES Act [Line Items]

Gross advance received for expansion of accelerated payments program in CARES Act

$ 15,700

Percentage of repayments due for first eleven months

25%

Percentage of payments recouped rate for another six months

50%

Percentage of reduction in payments

2%

Percentage of reduction of claim reimbursements

2%

1%

2%

2%

Pennsylvania DHS

Covid 19 CARES Act [Line Items]

Stimulus funds received CARES Act

4,800

Stimulus funds recognized as income CARES Act

500

Direct stimulus fund repaid CARES Act

$ 4,300

Other Than Pennsylvania

Covid 19 CARES Act [Line Items]

Stimulus funds received CARES Act

$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Jan. 01, 2022
Related Party Transaction [Line Items]
Management fees and expenses	$ 0	$ 0	$ 0	$ 900,000
Amounts owed in connection with advisory services agreements	$ 0		$ 0		$ 0
2021 Extended Term Loan
Related Party Transaction [Line Items]
Shareholders ownership percentage	6.80%		6.80%

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Oct. 01, 2022 Segment
Segment Reporting [Abstract]
Number of operating segments	3
Number of reportable segments	3

Segment Information - Summary o

Segment Information - Summary of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Segment Reporting Information [Line Items]
Revenue	$ 443,009	$ 411,276	$ 1,336,498	$ 1,264,548
Cost of revenue, excluding depreciation and amortization	308,426	271,534	912,046	846,534
Gross margin	$ 134,583	$ 139,742	$ 424,452	$ 418,014
Gross margin percentage	30.40%	34%	31.80%	33.10%
PDS
Segment Reporting Information [Line Items]
Revenue	$ 355,620	$ 327,133	$ 1,053,835	$ 1,027,640
Cost of revenue, excluding depreciation and amortization	254,756	226,540	753,266	719,435
Gross margin	$ 100,864	$ 100,593	$ 300,569	$ 308,205
Gross margin percentage	28.40%	30.70%	28.50%	30%
HHH
Segment Reporting Information [Line Items]
Revenue	$ 49,853	$ 47,000	$ 177,858	$ 128,589
Cost of revenue, excluding depreciation and amortization	32,968	24,130	98,933	67,224
Gross margin	$ 16,885	$ 22,870	$ 78,925	$ 61,365
Gross margin percentage	33.90%	48.70%	44.40%	47.70%
MS
Segment Reporting Information [Line Items]
Revenue	$ 37,536	$ 37,143	$ 104,805	$ 108,319
Cost of revenue, excluding depreciation and amortization	20,702	20,864	59,847	59,875
Gross margin	$ 16,834	$ 16,279	$ 44,958	$ 48,444
Gross margin percentage	44.80%	43.80%	42.90%	44.70%

Segment Information - Summary_2

Segment Information - Summary of Segment Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Segment Reconciliation:
Total segment gross margin	$ 134,583	$ 139,742	$ 424,452	$ 418,014
Branch and regional administrative expenses	89,542	76,370	267,283	223,462
Corporate expenses	33,215	37,873	105,984	97,673
Goodwill impairment			470,207
Depreciation and amortization	4,917	5,145	16,774	15,163
Acquisition-related costs		2,007	69	4,779
Other operating expense	2,122		1,953
Operating income (loss)	4,787	18,347	(437,818)	76,937
Interest income	164	44	369	182
Interest expense	(28,462)	(12,106)	(73,745)	(53,793)
Loss on debt extinguishment		(4,784)		(13,702)
Other income (expense)	45,140	(511)	86,523	(1,088)
Income (Loss) before income taxes	$ 21,629	$ 990	$ (424,671)	$ 8,536

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Summary of Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Numerator:
Net income (loss)	$ 24,298	$ 2,090	$ (424,255)	$ 9,148
Denominator:
Weighted average shares of common stock outstanding, basic	186,113	184,554	185,327	165,877
Net income (loss) per share, basic	$ 0.13	$ 0.01	$ (2.29)	$ 0.06
Weighted average shares of common stock outstanding, diluted	186,166	188,246	185,327	170,667
Net income (loss) per share, diluted	$ 0.13	$ 0.01	$ (2.29)	$ 0.05
RSUs
Denominator:
Dilutive securities outstanding not included in the computation of diluted net income (loss) per share as their effect is antidilutive:	4,684		4,722
PSUs
Denominator:
Dilutive securities outstanding not included in the computation of diluted net income (loss) per share as their effect is antidilutive:	1,368		1,368
Stock Options
Denominator:
Dilutive securities outstanding not included in the computation of diluted net income (loss) per share as their effect is antidilutive:	14,553	6,885	14,553	6,360